Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma.
about
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.Biological evaluation of 131I- and CF750-labeled Dmab(scFv)-Fc antibodies for xenograft imaging of CD25-positive tumors.A novel monoclonal antibody specific for canine CD25 (P4A10): selection and evaluation of canine TregsTrends in cancer immunotherapyA low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells.New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapiesImmunotherapy for ovarian cancer: what's next?The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.Treating rheumatic patients with a malignancy.Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomasInterleukin-2 at the crossroads of effector responses, tolerance, and immunotherapySam68 modulates the promoter specificity of NF-κB and mediates expression of CD25 in activated T cells.HTLV-1 and apoptosis: role in cellular transformation and recent advances in therapeutic approaches.Use of antibodies and immunoconjugates for the therapy of more accessible cancers.High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis.Bromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor κB (NF-κB) signalingAnalysis of human T-cell lymphotropic virus in CD25+ anaplastic large cell lymphoma in childrenTargetable molecular pathways in classical Hodgkin's lymphoma.New biologic-response modifiers in ocular inflammatory disease: beyond anti-TNF treatment.Relevance of radiobiological concepts in radionuclide therapy of cancer.Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis.Antibody therapy for Adult T-cell leukemia-lymphoma.Clinical features of de novo CD25(+) diffuse large B-cell lymphoma.Clinical features of de novo CD25-positive follicular lymphoma.Regulatory T Cells As Potential Targets for HIV Cure Research.Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology.
P2860
Q33346685-2612C746-A6BE-4EEB-9D46-3052335448BBQ33597766-08EBC9F2-57D6-489A-B85F-9466375BE132Q33830604-F35723A2-6F61-419D-B450-97EE23FF01B3Q34052702-D041D5E3-3C1E-4E50-ABF2-1A4125BD4BABQ34231824-148FF762-18BE-402C-94EB-C322A4BF950BQ34683488-9E46A708-B084-4CF9-BB8E-302E224ECA6EQ34743514-E5A0589E-12BC-4EF0-BCA0-08AB5A5E3711Q35058213-B1FD4967-F1E3-4B9E-B896-7C5A31800F22Q35557863-A582963B-48DA-4B21-98CD-E6A8FF56A557Q36183430-F396ACAC-C133-47C5-8692-6904F4461622Q36723728-50A4470E-0F22-4484-8726-97B039F98668Q36933399-C6EFF7A0-4AD6-4BF9-9DFD-5CA6C2AA13BAQ37079191-DAF5C8ED-1C6A-47F8-B35B-9090EFB29C9BQ37174938-E90E1439-F3C9-4647-ADAC-FE6DBCD38312Q37342927-8554F6C8-9C39-47EB-9540-CA18D06FE1B7Q37388856-BBFB43A2-216A-4841-8B54-80B57982DF69Q37407590-732DC545-9372-4916-954D-8AC70A9AC2E8Q37825891-52143C9A-8835-4D85-BF5D-240148E05A9FQ38057370-FB2FCFF7-B3F8-488E-9531-D0FC292FA951Q38751028-2F4D582C-D3E6-4B1A-95EA-AD2092FF3FD7Q39434495-6225E876-C618-491A-B1F6-C84BF8FBC311Q39698098-5FDA014C-F7D7-4808-AAF0-9FABE0C4A707Q45227780-BE055F80-2486-4E07-B1F0-CFFFED7073E2Q50970668-C4ECB71A-668D-40A5-9A4E-2774D5A1E472Q52715799-2525CCF6-A4A3-4F1B-9DFA-B1A9B2EA3912Q55386131-25300204-23F0-4B43-A0B3-122354CC6928
P2860
Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma.
@en
type
label
Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma.
@en
prefLabel
Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma.
@en
P2860
P356
P1433
P1476
Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma.
@en
P2093
T A Waldmann
P2860
P2888
P304
P356
10.1038/SJ.ONC.1210368
P407
P577
2007-05-01T00:00:00Z